Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

Abstract: The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (I): wherein X is alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, or substituted heteroalkenyl.

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

Abstract: The present invention, provides for a deuterium-enriched monoterpene or sesquiterpene such as perillyl alcohol, or a deuterium-enriched isomer or analog of monoterpenes or sesquiterpenes, such as isoperillyl alcohol. The present invention also provides for a deuterium-enriched derivative of a monoterpene or sesquiterpene, such as a perillyl alcohol carbamate or a deuterium-enriched derivative of an isomer or analog of a monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The deuterium-enriched derivative may be perillyl alcohol or isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a deuterium-enriched compound.

Abstract: The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.

Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Abstract: A system and method for determining a speed profile for a vehicle travelling along a road in which a curve speed estimation unit receives inputs indicating a position of the vehicle relative to a curve ahead of the vehicle, and inputs related to vehicle velocity, curve geometry, road surface conditions, vehicle-specific data; and driver preferences. The curve sped estimation unit use at least some of the above-listed inputs to determine a speed profile for the curve by generating an acceleration limit map which depends on a relationship between a maximum possible longitudinal acceleration and a maximum possible lateral acceleration.

Abstract: An arrangement, a vehicle and a method for providing vehicle driver support during manual or semi-autonomous driving in a potential overtake scenario are provided. The arrangement includes a detector, a communication unit arranged to receive from a preceding vehicle information of a probable route of the preceding vehicle based on at least one of preceding vehicle historical route information and preceding vehicle navigation system information, a processing unit arranged to determine, for one or more routes ahead of the host vehicle, the probability that the preceding vehicle will drive along the one or more route, to process the received information into a format suitable for display, and to display the processed information, thereby providing support to the vehicle driver.

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

Abstract: The present invention generally relates to a method, a system and/or a computer readable program. An embodiment of the method includes acquiring an input signal indicative of the operator's expectation of the state of the object at a first point in time; determining a state of the object at a second later point in time based on the input signal; acquiring an input signal indicative of an estimated visual input of the operator at the second point in time; determining the operator's expectation of the state at the second point in time, based on the operator's expectation of the state of the object at the first point in time, and the estimated visual input and the state of the object at the second point in time; and providing an output signal indicative of the operator's expectation of the state at the second point in time.

Abstract: The present invention generally relates to a method for improving the reliability of a portion of physiological data from an image sensor monitoring an operator positioned in an operator compartment of a vehicle. An embodiment of the method includes receiving, from the image sensor, physiological data including information relating to at least one of eye, face, head, arms and body motion of the operator, identifying an indication of at least an eyelid closure, eye movement or head movement of the operator based on the physiological data; comparing at least one of the physiological data and a lighting condition within the operator compartment with a set of rules for a current operator status; and classifying the type of eyelid closure, eye movement and/or head movement by correlating the identified eyelid closure, eye movement and/or head movement and a result of the comparison.

Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.

Abstract: System for improving a performance estimation of an operator of a vehicle, comprising a first module implementing a first method for estimating a performance state of vehicle operation, a second module implementing a second method for estimating at least one of a physiological and behavioral state of the operator, a device for sharing an estimated state between one of the first and the second module and the other one of the first and the second module, wherein the implemented estimation method of one of the first and the second module is adjusted based on the state of the other one of the first and the second module, thereby improving the estimation of at least one of the performance state of vehicle operation and the physiological and/or behavioral state of the operator.

Abstract: An arrangement, a vehicle and a method for providing vehicle driver support during manual or semi-autonomous driving in a potential overtake scenario are provided. The arrangement includes a detector, a communication unit arranged to receive from a preceding vehicle information of a probable route of the preceding vehicle based on at least one of preceding vehicle historical route information and preceding vehicle navigation system information, a processing unit arranged to determine, for one or more routes ahead of the host vehicle, the probability that the preceding vehicle will drive along the one or more route, to process the received information into a format suitable for display, and to display the processed information, thereby providing support to the vehicle driver.

Abstract: The present invention relates to a method for determining a vehicle operator's visual input of an object in the operator's surroundings, which method comprises receiving an object position signal indicative of the position of at least one object, receiving an operator motion input signal indicative of operator physiological data comprising information relating to body motion of the operator, estimating an operator eye-gaze direction, and determining a visual input quality value representative of level of visual input of the at least one object received by the operator, based on the object position signal and the estimated operator eye-gaze direction.

Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.